Protein & Cell >

2019 , Vol. 10 >Issue 8: 606 - 609

DOI: https://doi.org/10.1007/s13238-018-0602-z

LETTER

Developing potent PROTACs tools for selective degradation of HDAC6 protein

  • Zixuan An 1 ,
  • Wenxing Lv 2 ,
  • Shang Su 1 ,
  • Wei Wu , 1 ,
  • Yu Rao , 2
Expand
  • 1. MOE Key Laboratory of Protein Sciences, School of Life Sciences, Tsinghua University, Beijing 100084, China
  • 2. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing 100084, China

Published date: 15 Aug 2019

Copyright

2019 The Author(s)
Fold

Cite this article

Zixuan An , Wenxing Lv , Shang Su , Wei Wu , Yu Rao . Developing potent PROTACs tools for selective degradation of HDAC6 protein[J]. Protein & Cell, 2019 , 10(8) : 606 -609 . DOI: 10.1007/s13238-018-0602-z

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci (Lond) 130:987–1003

DOI

2
Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 55:9891–9899

DOI

3
Boettcher M, McManus MT (2015) Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 58:575–585

DOI

4
Davisson MT, Bergstrom DE, Reinholdt LG, Donahue LR (2012) Discovery genetics—the history and future of spontaneous mutation research. Curr Protoc Mouse Biol 2:103–118

DOI

5
El-Brolosy MA, Stainier DYR (2017) Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet 13: e1006780

DOI

6
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738

DOI

7
Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Van Leeuwen FW, Chanan-Khan AA (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281–3290

DOI

8
Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16:101–114

DOI

9
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J,Karasawa S, Carmel G, Jackson P,Abbasian M (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326–2335

DOI

10
Miyake Y, Keusch JJ, Wang L, Saito M, Hess D, Wang X, Melancon BJ, Helquist P, Gut H, Matthias P (2016) Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol 12:748–754

DOI

11
Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6: a018713

DOI

12
Sun YH, Zhao XW, Ding N, Gao HY, Wu Y, Yang YQ, Zhao M, Hwang J, Song YG, Liu WL (2018) PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 28:779–781

DOI

13
Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez- Madrid F (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18:291–297

DOI

14
Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W (2018) Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg Med Chem Lett 28:2493–2497

DOI

15
Zhou B, Hu JT, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y (2018) Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem 61:462–481

DOI

Options
Outlines

/

〈 〉